Tezacaftor

Tezacaftor
Clinical data
Other names	VX-661
License data	US DailyMed: Tezacaftor;
ATC code	R07AX31 (WHO), R07AX32 (WHO), R07AX33 (WHO);
Identifiers
	IUPAC name 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide;
CAS Number	1152311-62-0;
PubChem CID	46199646;
DrugBank	DB11712;
ChemSpider	28637762;
UNII	8RW88Y506K;
KEGG	D11041;
CompTox Dashboard (EPA)	DTXSID40673070 ;
Chemical and physical data
Formula	C26H27F3N2O6
Molar mass	520.505 g·mol−1
	InChI InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1; Key:MJUVRTYWUMPBTR-MRXNPFEDSA-N;

Tezacaftor is a medication used for the treatment of cystic fibrosis. It is available in fixed-dose combination medications.

The combination of tezacaftor with ivacaftor (brand name Symdeko) was approved for medical use in the United States in February 2018, and in Canada in June 2018. As brand name Symkevi it was approved for medical use in the European Union in October 2018.

The combination of tezacaftor with elexacaftor and ivacaftor (brand name Trikafta) was approved for medical use in the United States in October 2019, and in Canada in June 2021. As brand name Kaftrio it was approved for medical use in the European Union in August 2020.

The combination of tezacaftor with vanzacaftor and deutivacaftor (brand name Alyftrek) was approved for medical use in the United States in December 2024.